APP Pharmaceuticals, a Fresenius Kabi Company, has purchased three products, Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection, from Nexus Pharmaceuticals.
As per the agreement, APP acquires complete ownership and becomes the abbreviated new drug application holder of the products.
APP president and chief executive officer John Ducker said, "The addition of these products broadens an already extensive portfolio of injectable APP critical care products."
Benztropine Mesylate Injection, USP (1mg/mL, 2mL) is therapeutically equivalent to Cogentin. Levetiracetam Injection (100mg/ml, 5mL) is therapeutically equivalent Keppra.
Tranexamic Acid Injection (100 mg/mL, 10mL) is therapeutically equivalent to the reference-listed drug Cyklokapron.